Pulmonx (LUNG) Set to Announce Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is set to issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $19.30 million during the quarter, compared to analyst estimates of $18.24 million. Pulmonx had a negative net margin of 88.60% and a negative return on equity of 46.63%. Pulmonx’s revenue was up 25.3% compared to the same quarter last year. During the same period last year, the business earned ($0.38) EPS. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulmonx Stock Performance

Shares of NASDAQ LUNG opened at $7.50 on Tuesday. The firm’s 50-day moving average price is $8.92 and its 200-day moving average price is $10.72. The company has a quick ratio of 5.77, a current ratio of 6.50 and a debt-to-equity ratio of 0.30. The company has a market cap of $289.05 million, a PE ratio of -4.69 and a beta of 0.60. Pulmonx has a 52-week low of $7.11 and a 52-week high of $14.84.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a report on Wednesday, April 3rd. Stifel Nicolaus raised their price target on shares of Pulmonx from $15.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Citigroup raised their price target on shares of Pulmonx from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $14.00 price target (down previously from $16.00) on shares of Pulmonx in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.83.

Insider Buying and Selling

In other news, insider Geoffrey Beran Rose sold 3,097 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $9.06, for a total value of $28,058.82. Following the transaction, the insider now owns 239,952 shares of the company’s stock, valued at $2,173,965.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Pulmonx news, insider Geoffrey Beran Rose sold 3,097 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $9.06, for a total value of $28,058.82. Following the completion of the transaction, the insider now directly owns 239,952 shares in the company, valued at $2,173,965.12. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Glendon E. French III sold 20,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.60, for a total transaction of $292,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,121,344 shares of the company’s stock, valued at $16,371,622.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,032 shares of company stock valued at $469,012. 5.70% of the stock is owned by company insiders.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.